• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen to attend a lecture at AstraZeneca in Göteborg (Sweden) on May 29, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

Prof. Dario Neri gave a presentation entitled: “Tumor targeting: from encoded libraries to clinical-stage targeted therapeutics”

Philogen to attend the Immuno-Oncology Summit Europe in London (UK) on April 25, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

Prof. Dario Neri gave a presentation entitled: “Antibody-cytokine fusions directed against splice variants of fibronectin: from discovery to advanced clinical results”

Philogen to attend the European Association of Dermato-Oncology (EADO) Congress in Paris (France) on April 5, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

Prof. Dario Neri gave a presentation entitled: “Principles of ADC and bispecific antibodies”

Prof. Dario Neri to give a lecture at the University of Siena (Italy) on March 22, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

The lecture is entitled: “Encoded combinatorial libraries: from ligand discovery to targeted therapeutics”  

Philogen to attend the 10th ImmunoTherapy of Cancer (ITOC) Congress in Munich (Germany) on March 21, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

Prof. Dario Neri gave a presentation on Immunocytokines.

Prof. Dario Neri to give a lecture at the University of Milan (Italy) on February 19, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

The lecture given at the PhD Course in Pharmaceutical Sciences was entitled: “Encoded combinatorial libraries: from ligand discovery to targeted therapeutics”
« Older Entries
Next Entries »

Recent Posts

  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
  • The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)
  • Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
  • Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it